Multimodality vendor GE Healthcare has joined forces with Oxford University in Oxford, U.K., to study the pathology of colorectal cancer.
The two-year project will focus on improved staging of the disease using both imaging and genomic pathology, targeted therapy selection and efficacy assessment, and overall treatment monitoring, according to GE of Chalfont St. Giles, U.K.
By AuntMinnie.com staff writers
September 22, 2005
Related Reading
GE debuts Rediflo with Omnipaque, September 20, 2005
GE wins Chilean contract, September 16, 2005
GE, Daiichi extend collaboration, September 12, 2005
GE adds to Katrina donations, September 12, 2005
GE gets Innova CT clearance, September 7, 2005
Copyright © 2005 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
